Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Total Non-current Liabilities
All obligations due after more than one year.
Alto Neuroscience, Inc.NYSE: ANRO
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 22.6% from a year ago
Total non-current liabilities stood at $19.78M at the end of Q1 FY2026, down 22.6% from a year earlier and down 11.0% from the prior quarter. Over 3 fiscal years it compounded at -35.7% a year.
Context
- Total non-current liabilities amounted to 7.2% of total assets at the end of Q1 FY2026, down 7.7 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -22.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 22.22M USD
- Year-over-year change
- +38.2%
- 4-year CAGR
- -13.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.22M | +38.2% |
| FY2024 | 2024-12-31 | 16.07M | -89.5% |
| FY2023 | 2023-12-31 | 152.69M | +82.4% |
| FY2022 | 2022-12-31 | 83.7M | +112.1% |
| FY2021 | 2021-12-31 | 39.46M | — |
Total Non-current Liabilities vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -22.6% is the 8th highest of 11, against a peer median of -11.5%.
- Total non-current liabilities amounts to 7.2% of total assets for ANRO, versus a peer median of 6.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.77M USD | +11.1% | +12.6% | 32.8% | |
| Mar 2026 | $55.26M USD | -80.2% | -4.4% | 48.0% | |
| Mar 2026 | $49.2M USD | -2.3% | -32.6% | 26.8% | |
| Mar 2026 | $28.97M USD | +95.3% | +23.2% | 26.6% | |
| Mar 2026 | $19.78M USD | -22.6% | -35.7% | 7.2% | |
| Mar 2026 | $16.71M USD | -14.7% | -18.4% | 2.6% | |
| Mar 2026 | CHF 13.64M CHF | -19.9% | +39.0% | 9.9% | |
| Mar 2026 | $6.7M USD | -8.3% | -32.5% | 2.5% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $4.65M USD | +2.3% | +15.7% | 1.8% |
| Mar 2026 | $2.72M USD | -27.8% | -14.8% | 1.3% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding ANRO) | — | -11.5% | -4.4% | 6.3% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.71M | 48.34M | 82.55M | 168.23M | 176.48M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.74M | 546K | 8K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 2.31M | 30K | 1.23M |
| Total Current Assets | 27.68M | 49.22M | 85.39M | 169.34M | 177.72M |
| Property, Plant & Equipment (Net) | 1.06M | 1.58M | 1.11M | 7.7M | 6.13M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 500K | 500K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 50K | 55K | 131K | 4K | 338K |
| Total Non-current Assets | 1.11M | 1.63M | 1.24M | 8.21M | 6.97M |
| Total Assets | 28.79M | 50.85M | 86.63M | 177.54M | 184.69M |
| Account Payables | 600K | 1.61M | 1.07M | 1.58M | 1.88M |
| Short-term Debt | 0 | 283K | 0 | 0 | 585K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.19M | 3.54M | 0 | 0 | 8.86M |
| Total Current Liabilities | 1.81M | 5.56M | 5.61M | 10.01M | 11.33M |
| Long-term Debt | 38.16M | 81.7M | 9.86M | 11.56M | 3.82M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.3M | 1.88M | 142.83M | 0 | 18.4M |
| Total Non-current Liabilities | 39.46M | 83.7M | 152.69M | 16.07M | 22.22M |
| Total Liabilities | 41.27M | 89.26M | 158.3M | 26.08M | 33.55M |
| Common Stock | 1K | 1K | 0 | 3K | 3K |
| Retained Earnings | (12.95M) | (40.66M) | (76.97M) | (138.4M) | (201.63M) |
| Accumulated OCI | (22K) | (46K) | (79K) | (101K) | 22K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (12.48M) | (38.41M) | (71.67M) | 151.46M | 151.14M |
| Total Debt | 38.16M | 82.11M | 9.99M | 16.94M | 4.41M |
| Net Debt | 12.46M | 33.76M | (72.56M) | (151.29M) | (172.08M) |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.